Seven Eight Capital LP Takes $2.79 Million Position in DaVita Inc. (NYSE:DVA)

Seven Eight Capital LP purchased a new stake in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 20,146 shares of the company’s stock, valued at approximately $2,792,000.

A number of other institutional investors also recently bought and sold shares of DVA. SG Americas Securities LLC grew its holdings in DaVita by 196.9% during the 1st quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock valued at $4,105,000 after purchasing an additional 19,719 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of DaVita by 2,335.6% during the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after acquiring an additional 10,300 shares during the last quarter. Forsta AP Fonden boosted its holdings in DaVita by 50.3% during the 1st quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock valued at $3,258,000 after acquiring an additional 7,900 shares during the period. Fox Hill Wealth Management grew its position in DaVita by 138.4% in the 1st quarter. Fox Hill Wealth Management now owns 15,734 shares of the company’s stock valued at $2,172,000 after acquiring an additional 9,135 shares during the last quarter. Finally, Sei Investments Co. increased its stake in DaVita by 21.3% in the first quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock worth $5,790,000 after purchasing an additional 7,371 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 0.6 %

NYSE:DVA opened at $164.19 on Wednesday. The stock has a market capitalization of $13.78 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.90 and a beta of 0.87. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The company’s 50-day simple moving average is $145.73 and its 200-day simple moving average is $140.27.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.08 EPS. On average, equities analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the SEC, which is available at this link. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock valued at $27,387,069 in the last 90 days. 2.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. TD Cowen increased their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group boosted their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average price target of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.